热门资讯> 正文

Travere Therapeutics任命Bradley Campbell为首席执行官，取代Eric Dube

2026-09-22 04:24

Travere Therapeutics (TVTX) has appointed Bradley Campbell as chief executive officer, effective December 1, 2026, the compnay said on Monday.
The announcement came after Eric Dube said he will step down as CEO and president to focus on his health and family.
Campbell was the former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical.
Source: Press Release

More on Travere Therapeutics

Travere Therapeutics: Valuation Suggests A Buy
Travere Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)
Travere signals potential for more than $3B in peak annual FILSPARI sales as FSGS launch exceeds expectations
Travere Therapeutics Non-GAAP EPS of -$0.10 misses by $0.42, revenue of $161.4M beats by $4.13M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。